Physician profile
Joan E King
NPI 1770567232
$2,762.64
in general payments reported to CMS, 2019-2025
31 companies · $25.30 in 2025
The $25.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $403 · 2021: $683 · 2022: $422 · 2025: $25.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $515.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $232.87 | 2019-2021 | |
| Amarin Pharma, INC. | $209.28 | 2019-2021 | |
| Pfizer INC. | $184.08 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $177.55 | 2021 | |
| Astellas Pharma US INC | $170.28 | 2019 | |
| Novo Nordisk INC | $166.72 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $166.25 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $140.79 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $108.47 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.05 | 2020-2022 | |
| Abbvie INC. | $68.71 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $65.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.02 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.77 | 2019-2021 | |
| Dexcom, INC. | $33.04 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.51 | 2022 | |
| Neos Therapeutics, Lp | $26.96 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $25.30 | 2025 | |
| Arbor Pharmaceuticals, INC. | $22.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2021 | |
| Eisai INC. | $21.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.96 | 2022 | |
| Abbott Laboratories | $18.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.28 | 2022 | |
| Electromed, INC. | $15.38 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.65 | 2019 | |
| Daiichi Sankyo INC. | $14.54 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.20 | 2022 | |
| Ibsa Pharma INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.